[{"orgOrder":0,"company":"STEERLife India Pvt. Ltd","sponsor":"Bionpharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Inapplicable","leadProduct":"Etravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"STEERLife India Pvt. Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"STEERLife India Pvt. Ltd \/ STEERLife India Pvt. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"STEERLife India Pvt. Ltd \/ STEERLife India Pvt. Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by STEERLife India Pvt. Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : Etravirine, a miscellaneous product, targets human immunodeficiency virus type 1 reverse transcriptase, focusing on treating HIV/AIDS.

                          Product Name : Intelence-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2026

                          Lead Product(s) : Etravirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Bionpharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank